Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies

Oncogene volume 36, pages 3629–3639 (2017)Cite this article

Subjects

Abstract

Miniature chromosome maintenance (MCM) proteins play critical roles in DNA replication licensing, initiation and elongation. MCM8, one of the MCM proteins playing a critical role in DNA repairing and recombination, was found to have overexpression and increased DNA copy number in a variety of human malignancies. The gain of MCM8 is associated with aggressive clinical features of several human cancers. Increased expression of MCM8 in prostate cancer is associated with cancer recurrence. Forced expression of MCM8 in RWPE1 cells, the immortalized but non-transformed prostate epithelial cell line, exhibited fast cell growth and transformation, while knock down of MCM8 in PC3, DU145 and LNCaP cells induced cell growth arrest, and decreased tumour volumes and mortality of severe combined immunodeficiency mice xenografted with PC3 and DU145 cells. MCM8 bound cyclin D1 and activated Rb protein phosphorylation by cyclin-dependent kinase 4 in vitro and in vivo. The cyclin D1/MCM8 interaction is required for Rb phosphorylation and S-phase entry in cancer cells. As a result, our study showed that copy number increase and overexpression of MCM8 may play critical roles in human cancer development.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics, 2008. CA Cancer J Clin 2008; 58: 71–96.

    Article  PubMed  Google Scholar 

  2. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ . Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225–249.

    Article  PubMed  Google Scholar 

  3. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A et al. Colorectal cancer statistics, 2017. CA Cancer J Clin 2017. Available from: http://onlinelibrary.wiley.com/doi/10.3322/caac.21395/full.

  4. Network TCGAR. The molecular taxonomy of primary prostate cancer. Cell 2015; 163: 1011–1025.

    Article  Google Scholar 

  5. Weinstein JN, Collisson EA, Mills GB, Shaw KR, Ozenberger BA, Ellrott K et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013; 45: 1113–1120.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Ciriello G, Miller ML, Aksoy BA, Senbabaoglu Y, Schultz N, Sander C . Emerging landscape of oncogenic signatures across human cancers. Nat Genet 2013; 45: 1127–1133.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Zack TI, Schumacher SE, Carter SL, Cherniack AD, Saksena G, Tabak B et al. Pan-cancer patterns of somatic copy number alteration. Nat Genet 2013; 45: 1134–1140.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Yu YP, Ding Y, Chen R, Liao SG, Ren BG, Michalopoulos A et al. Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer. Am J Pathol 2013; 183: 1960–1970.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Luo JH, Ding Y, Chen R, Michalopoulos G, Nelson J, Tseng G et al. Genome-wide methylation analysis of prostate tissues reveals global methylation patterns of prostate cancer. Am J Pathol 2013; 182: 2028–2036.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Yu YP, Song C, Tseng G, Ren BG, Laframboise W, Michalopoulos G et al. Genome abnormalities precede prostate cancer and predict clinical relapse. Am J Pathol 2012; 180: 2240–2248.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  11. Yu YP, Landsittel D, Jing L, Nelson J, Ren B, Liu L et al. Gene expression alterations in prostate cancer predicting tumor aggression and preceding development of malignancy. J Clin Oncol 2004; 22: 2790–2799.

    Article  CAS  PubMed  Google Scholar 

  12. Luo JH, Yu YP, Cieply K, Lin F, Deflavia P, Dhir R et al. Gene expression analysis of prostate cancers. Mol Carcinog 2002; 33: 25–35.

    Article  CAS  PubMed  Google Scholar 

  13. Luo JH . Gene expression alterations in human prostate cancer. Drugs Today (Barc) 2002; 38: 713–719.

    Article  CAS  Google Scholar 

  14. Hansen KD, Timp W, Bravo HC, Sabunciyan S, Langmead B, McDonald OG et al. Increased methylation variation in epigenetic domains across cancer types. Nat Genet 2011; 43: 768–775.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Feber A, Wilson GA, Zhang L, Presneau N, Idowu B, Down TA et al. Comparative methylome analysis of benign and malignant peripheral nerve sheath tumors. Genome Res 2011; 21: 515–524.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  16. Vallot C, Stransky N, Bernard-Pierrot I, Herault A, Zucman-Rossi J, Chapeaublanc E et al. A novel epigenetic phenotype associated with the most aggressive pathway of bladder tumor progression. J Natl Cancer Inst 2011; 103: 47–60.

    Article  CAS  PubMed  Google Scholar 

  17. Yu YP, Paranjpe S, Nelson J, Finkelstein S, Ren B, Kokkinakis D et al. High throughput screening of methylation status of genes in prostate cancer using an oligonucleotide methylation array. Carcinogenesis 2005; 26: 471–479.

    Article  CAS  PubMed  Google Scholar 

  18. Edwards MC, Tutter AV, Cvetic C, Gilbert CH, Prokhorova TA, Walter JC . MCM2-7 complexes bind chromatin in a distributed pattern surrounding the origin recognition complex in Xenopus egg extracts. J Biol Chem 2002; 277: 33049–33057.

    Article  CAS  PubMed  Google Scholar 

  19. Blow JJ, Hodgson B . Replication licensing—defining the proliferative state? Trends Cell Biol 2002; 12: 72–78.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Labib K, Kearsey SE, Diffley JF . MCM2-7 proteins are essential components of prereplicative complexes that accumulate cooperatively in the nucleus during G1-phase and are required to establish, but not maintain, the S-phase checkpoint. Mol Biol Cell 2001; 12: 3658–3667.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Lu ZH, Xu H, Leno GH . DNA replication in quiescent cell nuclei: regulation by the nuclear envelope and chromatin structure. Mol Biol Cell 1999; 10: 4091–4106.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Honeycutt KA, Chen Z, Koster MI, Miers M, Nuchtern J, Hicks J et al. Deregulated minichromosomal maintenance protein MCM7 contributes to oncogene driven tumorigenesis. Oncogene 2006; 25: 4027–4032.

    Article  CAS  PubMed  Google Scholar 

  23. Luo JH . Oncogenic activity of MCM7 transforming cluster. World J Clin Oncol 2011; 2: 120–124.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Laitinen S, Martikainen PM, Tolonen T, Isola J, Tammela TL, Visakorpi T . EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer 2008; 122: 595–602.

    Article  CAS  PubMed  Google Scholar 

  25. Ren B, Yu G, Tseng GC, Cieply K, Gavel T, Nelson J et al. MCM7 amplification and overexpression are associated with prostate cancer progression. Oncogene 2006; 25: 1090–1098.

    Article  CAS  PubMed  Google Scholar 

  26. Shohet JM, Hicks MJ, Plon SE, Burlingame SM, Stuart S, Chen SY et al. Minichromosome maintenance protein MCM7 is a direct target of the MYCN transcription factor in neuroblastoma. Cancer Res 2002; 62: 1123–1128.

    CAS  PubMed  Google Scholar 

  27. Padmanabhan V, Callas P, Philips G, Trainer TD, Beatty BG . DNA replication regulation protein Mcm7 as a marker of proliferation in prostate cancer. J Clin Pathol 2004; 57: 1057–1062.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Facoetti A, Ranza E, Benericetti E, Ceroni M, Tedeschi F, Nano R . Minichromosome maintenance protein 7: a reliable tool for glioblastoma proliferation index. Anticancer Res 2006; 26: 1071–1075.

    CAS  PubMed  Google Scholar 

  29. Feng CJ, Li HJ, Li JN, Lu YJ, Liao GQ . Expression of Mcm7 and Cdc6 in oral squamous cell carcinoma and precancerous lesions. Anticancer Res 2008; 28: 3763–3769.

    CAS  PubMed  Google Scholar 

  30. Freeman A, Morris LS, Mills AD, Stoeber K, Laskey RA, Williams GH et al. Minichromosome maintenance proteins as biological markers of dysplasia and malignancy. Clin Cancer Res 1999; 5: 2121–2132.

    CAS  PubMed  Google Scholar 

  31. Iizuka N, Tsunedomi R, Tamesa T, Okada T, Sakamoto K, Hamaguchi T et al. Involvement of c-myc-regulated genes in hepatocellular carcinoma related to genotype-C hepatitis B virus. J Cancer Res Clin Oncol 2006; 132: 473–481.

    Article  CAS  PubMed  Google Scholar 

  32. van Dekken H, Tilanus HW, Hop WC, Dinjens WN, Wink JC, Vissers KJ et al. Array comparative genomic hybridization, expression array, and protein analysis of critical regions on chromosome arms 1q, 7q, and 8p in adenocarcinomas of the gastroesophageal junction. Cancer Genet Cytogenet 2009; 189: 37–42.

    Article  CAS  PubMed  Google Scholar 

  33. Nishihara K, Shomori K, Fujioka S, Tokuyasu N, Inaba A, Osaki M et al. Minichromosome maintenance protein 7 in colorectal cancer: implication of prognostic significance. Int J Oncol 2008; 33: 245–251.

    CAS  PubMed  Google Scholar 

  34. Fujioka S, Shomori K, Nishihara K, Yamaga K, Nosaka K, Araki K et al. Expression of minichromosome maintenance 7 (MCM7) in small lung adenocarcinomas (pT1): prognostic implication. Lung Cancer (Amsterdam, Netherlands) 2009; 65: 223–229.

    Article  Google Scholar 

  35. Ota T, Clayton AC, Minot DM, Shridhar V, Hartmann LC, Gilks CB et al. Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. Mod Pathol 2011; 24: 277–287.

    Article  CAS  PubMed  Google Scholar 

  36. Fristrup N, Birkenkamp-Demtroder K, Reinert T, Sanchez-Carbayo M, Segersten U, Malmstrom PU et al. Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol 2013; 182: 339–349.

    Article  CAS  PubMed  Google Scholar 

  37. Zhou YM, Zhang XF, Cao L, Li B, Sui CJ, Li YM et al. MCM7 expression predicts post-operative prognosis for hepatocellular carcinoma. Liver Int 2012; 32: 1505–1509.

    Article  CAS  PubMed  Google Scholar 

  38. Kang W, Tong JH, Chan AW, Cheng AS, Yu J, To K . MCM7 serves as a prognostic marker in diffuse-type gastric adenocarcinoma and siRNA-mediated knockdown suppresses its oncogenic function. Oncol Rep 31: 2071–2078.

    Article  CAS  PubMed  Google Scholar 

  39. Matsushime H, Ewen ME, Strom DK, Kato JY, Hanks SK, Roussel MF et al. Identification and properties of an atypical catalytic subunit (p34PSK-J3/cdk4) for mammalian D type G1 cyclins. Cell 1992; 71: 323–334.

    Article  CAS  PubMed  Google Scholar 

  40. Kato J, Matsushime H, Hiebert SW, Ewen ME, Sherr CJ . Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4. Genes Dev 1993; 7: 331–342.

    Article  CAS  PubMed  Google Scholar 

  41. Maiorano D, Cuvier O, Danis E, Mechali M . MCM8 is an MCM2-7-related protein that functions as a DNA helicase during replication elongation and not initiation. Cell 2005; 120: 315–328.

    Article  CAS  PubMed  Google Scholar 

  42. Volkening M, Hoffmann I . Involvement of human MCM8 in prereplication complex assembly by recruiting hcdc6 to chromatin. Mol Cell Biol 2005; 25: 1560–1568.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. Gozuacik D, Chami M, Lagorce D, Faivre J, Murakami Y, Poch O et al. Identification and functional characterization of a new member of the human Mcm protein family: hMcm8. Nucleic Acids Res 2003; 31: 570–579.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  44. Lee KY, Im JS, Shibata E, Park J, Handa N, Kowalczykowski SC et al. MCM8-9 complex promotes resection of double-strand break ends by MRE11-RAD50-NBS1 complex. Nat Commun 6: 7744.

  45. Park J, Long DT, Lee KY, Abbas T, Shibata E, Negishi M et al. The MCM8-MCM9 complex promotes RAD51 recruitment at DNA damage sites to facilitate homologous recombination. Mol Cell Biol 2013; 33: 1632–1644.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Lutzmann M, Grey C, Traver S, Ganier O, Maya-Mendoza A, Ranisavljevic N et al. MCM8- and MCM9-deficient mice reveal gametogenesis defects and genome instability due to impaired homologous recombination. Mol Cell 47: 523–534.

    Article  CAS  PubMed  Google Scholar 

  47. AlAsiri S, Basit S, Wood-Trageser MA, Yatsenko SA, Jeffries EP, Surti U et al. Exome sequencing reveals MCM8 mutation underlies ovarian failure and chromosomal instability. J Clin Invest 125: 258–262.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Kato JY, Matsuoka M, Polyak K, Massague J, Sherr CJ . Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. Cell 1994; 79: 487–496.

    Article  CAS  PubMed  Google Scholar 

  49. Toyoshima H, Hunter T . p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. Cell 1994; 78: 67–74.

    Article  CAS  PubMed  Google Scholar 

  50. Xiong Y, Zhang H, Beach D . Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation. Genes Dev 1993; 7: 1572–1583.

    Article  CAS  PubMed  Google Scholar 

  51. Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, Beach D . p21 is a universal inhibitor of cyclin kinases. Nature 1993; 366: 701–704.

    Article  CAS  PubMed  Google Scholar 

  52. Stepanova L, Leng X, Parker SB, Harper JW . Mammalian p50Cdc37 is a protein kinase-targeting subunit of Hsp90 that binds and stabilizes Cdk4. Genes Dev 1996; 10: 1491–1502.

    Article  CAS  PubMed  Google Scholar 

  53. Dai K, Kobayashi R, Beach D . Physical interaction of mammalian CDC37 with CDK4. J Biol Chem 1996; 271: 22030–22034.

    Article  CAS  PubMed  Google Scholar 

  54. Xiong Y, Zhang H, Beach D . D type cyclins associate with multiple protein kinases and the DNA replication and repair factor PCNA. Cell 1992; 71: 505–514.

    Article  CAS  PubMed  Google Scholar 

  55. Zhang JM, Wei Q, Zhao X, Paterson BM . Coupling of the cell cycle and myogenesis through the cyclin D1-dependent interaction of MyoD with cdk4. EMBO J 1999; 18: 926–933.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  56. Kearsey SE, Maiorano D, Holmes EC, Todorov IT . The role of MCM proteins in the cell cycle control of genome duplication. Bioessays 1996; 18: 183–190.

    Article  CAS  PubMed  Google Scholar 

  57. Shi YK, Yu YP, Zhu ZH, Han YC, Ren B, Nelson JB et al. MCM7 interacts with androgen receptor. Am J Pathol 2008; 173: 1758–1767.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Han YC, Zheng ZL, Zuo ZH, Yu YP, Chen R, Tseng GC et al. Metallothionein 1 h tumour suppressor activity in prostate cancer is mediated by euchromatin methyltransferase 1. J Pathol 2013; 230: 184–193.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  59. Wang H, Luo K, Tan LZ, Ren BG, Gu LQ, Michalopoulos G et al. p53-induced gene 3 mediates cell death induced by glutathione peroxidase 3. J Biol Chem 2012; 287: 16890–16902.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  60. Han YC, Yu YP, Nelson J, Wu C, Wang H, Michalopoulos GK et al. Interaction of integrin-linked kinase and miniature chromosome maintenance 7-mediating integrin {alpha}7 induced cell growth suppression. Cancer Res 2010; 70: 4375–4384.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Ren B, Yu YP, Tseng GC, Wu C, Chen K, Rao UN et al. Analysis of integrin alpha7 mutations in prostate cancer, liver cancer, glioblastoma multiforme, and leiomyosarcoma. J Natl Cancer Inst 2007; 99: 868–880.

    Article  CAS  PubMed  Google Scholar 

  62. Jing L, Liu L, Yu YP, Dhir R, Acquafondada M, Landsittel D et al. Expression of myopodin induces suppression of tumor growth and metastasis. Am J Pathol 2004; 164: 1799–1806.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Yu YP, Tseng GC, Luo JH . Inactivation of myopodin expression associated with prostate cancer relapse. Urology 2006; 68: 578–582.

    Article  PubMed  Google Scholar 

  64. Yu YP, Luo JH . Myopodin-mediated suppression of prostate cancer cell migration involves interaction with zyxin. Cancer Res 2006; 66: 7414–7419.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by grants from National Cancer Institute (RO1 CA098249) to JHL and a grant from University of Pittsburgh Cancer Institute.

Author information

Authors and Affiliations

  1. Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    D-M He, B-G Ren, L-Z Tan, K Cieply, Y P Yu & J-H Luo

  2. Department of Biostatistics, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA

    S Liu & G Tseng

Authors
  1. D-M He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B-G Ren
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. S Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. L-Z Tan
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. K Cieply
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. G Tseng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Y P Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. J-H Luo
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to J-H Luo.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies this paper on the Oncogene website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

He, DM., Ren, BG., Liu, S. et al. Oncogenic activity of amplified miniature chromosome maintenance 8 in human malignancies. Oncogene 36, 3629–3639 (2017). https://doi.org/10.1038/onc.2017.123

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/onc.2017.123

This article is cited by

Search

Advanced search

Quick links